<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956432</url>
  </required_header>
  <id_info>
    <org_study_id>SHR4640-303</org_study_id>
    <nct_id>NCT04956432</nct_id>
  </id_info>
  <brief_title>A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout</brief_title>
  <official_title>A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the serum uric acid lowering effects and safety of SHR4640 compared to&#xD;
      Allopurinol in subjects with gout.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>To evaluate the efficacy and safety of SHR4640 monotherapy tablets in patients with gout</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a serum uric acid level≤360 μmol/L</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change in serum uric acid from baseline at each visit during 16 weeks of treatment</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute changes in serum uric acid from baseline at each visit during 16 weeks of treatment</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with A serum uric acid level≤ 360 μmol/L at each visit within 16 weeks of treatment</measure>
    <time_frame>Start of Treatment to end of study (approximately 16 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR4640+Allopurinol Placebo；once a day, orally, for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Allopurinol+ SHR4640 Placebo；once a day, orally, for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR4640</intervention_name>
    <description>SHR4640 Dose 1 ,tablets, QD</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 300mg, tablets, QD</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject who met 1977 or 2015 ACR (American College of Rheumatology) classification of&#xD;
             Gout and has a serum acid ≥ 480 μmol/L at screening; 2、18 kg/m2 ≤ Body mass index&#xD;
             (BMI) ≤ 35 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject who is pregnant or breastfeeding;&#xD;
&#xD;
          2. Alanine aminotransferase or Aspartate aminotransferase or total bilirubin&gt;1.5 upper&#xD;
             normal limit;&#xD;
&#xD;
          3. Subject with a positive test for HLA-B*5801;&#xD;
&#xD;
          4. Estimated glomerular filtration rate (MDRD formula) &lt;60ml/min;&#xD;
&#xD;
          5. HbA1c≥8%;&#xD;
&#xD;
          6. Subject with known hypersensitivity or allergy to SHR4640 and allopurinol, or any&#xD;
             component of SHR4640;&#xD;
&#xD;
          7. Subject with kidney stones or suspicion of kidney stones;&#xD;
&#xD;
          8. Subject who has acute gout flares within 2 weeks before randomization;&#xD;
&#xD;
          9. Subject with a history of malignancy within the previous 5 years;&#xD;
&#xD;
         10. Subject with a history of active peptic ulcer within a year;&#xD;
&#xD;
         11. Subject with a history of xanthine urine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FEI LUO</last_name>
    <phone>18036618807</phone>
    <email>fei.luo@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>RenJi Hospital, Shanghai JiaoTong University School Of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunde Bao, Doctor</last_name>
      <phone>+86-13601689747</phone>
      <email>baochunde_1678@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

